Purpose To evaluate the therapeutic impact of [
Introduction
Despite advanced imaging technology, diagnostic results after magnetic resonance (MR) and/or computed tomography (CT) imaging in patients suffering from foot pain may remain inconclusive. The combination of morphological and functional imaging using fluoride positron-emission tomography/computed tomography (PET/CT) bears the potential to allow us to obtain a better three-dimensional appreciation of morphology, together with metabolism, thereby arriving at a more specific diagnosis. As a result, it may alter and/or improve therapeutic management. Tc-labeled bone seeking agents such as methylene diphosphonate (MDP) were subsequently preferred for bone scanning. In the early 1990s [ [ 18 F]fluoride is a tracer that mainly depicts blood flow and osteoblastic activity. After intravenous (i.v.) administration, [ 18 F]fluoride runs through the bone capillaries and diffuses into the bone extracellular fluid (ECF). Its plasma clearance is more rapid, and its single-passage extraction efficiency is higher, than that of 99m Tc-MDP due to its smaller molecular weight and its negligible protein binding. Uptake is into hydroxyapatite crystals, which form the mineral fluoroapatite within the bone, especially at sites of bone remodeling. Its bone uptake is approximately twotimes greater than that of the conventional tracer 99m Tc-MDP, and its blood-to-bone clearance reaches almost 100%, with the fast bone clearance resulting in a better target-to-background ratio. As a further advantage, [ 18 F] fluoride allows imaging shortly (approximately 30 min) after i.v. administration, in contrast to the significantly longer uptake times of 99m Tc-MDP [2, 3] . Several studies have analyzed [ 18 F]fluoride uptake in patients with malignant and benign diseases in various regions of the human skeleton using PET only or PET/CT. Encouraging results have been published regarding the detection of bone metastasis from breast cancer, lung cancer, and thyroid and prostate cancers [4] [5] [6] [7] [8] .
It has also been shown that planar bone scintigraphy has a significantly lower accuracy in detecting bone metastases than has combined bone scintigraphy and single-photon emission computed tomography (SPECT) or [ [3, 9, 10] , few studies are available that have defined the role of static [ 18 F]fluoride PET/(CT) for the evaluation of non-malignant bone disorders [3, [11] [12] [13] [14] . Recently promising results of SPECT/CT imaging in patients with foot pain have been published [15, 16] . Owing to a worldwide shortage of molybdenum, [ 18 F] fluoride has become more and more attractive as an alternative bone tracer [17, 18] .
The purpose of our study was to evaluate the therapeutic impact of [ 18 F]fluoride PET/CT imaging on patients with unclear foot pain. It was hypothesized that [ 18 F]fluoride PET/CT may be able to specify the diagnosis better and, as a consequence, influence further treatment strategies.
Patients and methods

Patient selection
Twenty-eight patients (14 female and 14 male; mean age 47 years, age range 33-70 years) with foot pain were prospectively enrolled in this study between November 2007 and February 2009. For these patients the specific diagnosis for this condition had remained inconclusive after clinical examination and/or imaging with magnetic resonance imaging (MRI) and/or CT. The study was approved by our institutional review board (IRB), and the written informed consent of each patient was obtained.
Nine (32%) patients had a history of both trauma and surgery; three patients (10%) had a history of surgery only, one of them due to hemophilic arthropathy/implantation of a talotibial joint arthrodesis, one due to debridement because of a subtalar arthropathy, one due to osteochondrosis dissecans of the talus and implantation of a talotibial joint prosthesis; nine (32%) patients had a history of trauma without surgery, and seven (25%) had had neither a history of surgery nor trauma. Patients had foot pain either in the left foot (14/28; 50%), right foot (11/28; 40%), or both feet (3/28; 11%). Twenty-one patients had undergone prior MRI; two patients had undergone CT, and three both MRI and CT (one of the latter had had a CT scan with intra-articular injection of contrast medium), which all remained inconclusive regarding the origin of the foot pain. The acquired images were post-processed with dedicated software (AW workstation, GE Health Systems) providing multiplanar reformatted images for PET alone, CT alone and fused PET/CT with linked cursors.
Radiochemistry
PET/CT evaluation PET/CT images were analyzed by a dual board certified radiologist and nuclear physician with special training in musculoskeletal radiology and 5 years' experience in PET/ CT reading. The reader was unaware of the results of prior imaging examinations. Attenuation-corrected PET images were used for analysis. The PET images were evaluated for the presence and nature of focal lesions with increased [
18 F]fluoride uptake in both feet and lower limbs. Increased uptake of [ 18 F]fluoride higher than by normal appearing bone was interpreted as pathologic, regardless whether or not pathological changes were visible on CT scans. The thin-slice CT data were used for exact anatomic correlation with fluoride uptake and were analyzed for additional fluoride-PET negative important morphological findings.
Patient treatment
Two experienced foot and ankle surgeons were asked to define, first, the therapeutic management without the data from the PET/CT examination, and second, the therapeutic management with the data from the PET/ CT-examination.
All 28 patients had had foot pain for between 4 months and 84 months (mean 27.4 months) prior to undergoing PET/CT. As their foot pain remained unclear after the clinical examination and the suggestion of soft-tissue pathology was raised, the patients were primarily sent for MRI ( 24 patients). In four patients the indication for [
18 F] fluoride PET/CT was given, due to clinical suggestion of degenerative joint disease (two of hindfoot osteoarthritis, two of loosening of a talotibial joint prosthesis with possible osteoarthritis of the subtalar joint).
After all 28 patients had undergone [ 18 F]fluoride PET/ CT, the diagnoses were compared with the diagnoses before the PET/CT, and the two surgeons decided whether the therapeutic management had to be changed.
Retrospective analysis of MR diagnoses when a therapy change occurred after PET/CT
A radiologist with 16 years experience in musculoskeletal imaging retrospectively evaluated the MR images of those 13 patients for whom therapeutic management had been changed after PET/CT. In 11/13 of the patients an MRI scan was available with a time interval of 2 days to 6 months prior to the PET/CT imaging. First, the MR images were evaluated with the reader unaware of the clinical data and PET/CT findings. Second, the PET/CT findings were retrospectively compared with those of the MRI. Nine of the 11 MR examinations were performed according to the in-house protocol, consisting of five MR pulse sequences [short-tau inversion recovery (STIR) sagittal; T1-weighted (T1-w) and T2-weighted (T2-w) coronal; T2-w axial, and one angled T1-w axial]. Two MR examinations had been performed in an outside institution with a similar MR protocol, including a STIR sequence and one with the i.v. administration of contrast agent ( Table 2) .
Results
PET/CT findings
In 13/28 (46%) patients therapeutic management was changed, based on the results of [
18 F]fluoride PET/CT imaging. Of these 13 patients, nine (69%) had pain in their left foot, 1/13 (8%) in the right foot, and 3/13 (23%) in both feet. Four of the 13 (31%) had a history of trauma, 4/13 (31%) a history of trauma and surgery, and 5/13 (38%) had had neither trauma nor surgery.
The main diagnoses in those patients with pain in their left foot (9/13) were as follows: os trigonum syndrome; sinus tarsi syndrome; osteoarthritis of the talotibial joint, including the talofibular space and a non-consolidated fragment of the anterior calcaneal process; non-union after distal tibial fracture; increased activity at the lateral calcaneal bone (possibly a periostitis); a non-consolidated fragment of the left anterior calcaneal process; a calcaneonavicular coalition without significant activity; osteoarthritis of the talonavicular joint and a subtalar osteoarthritis and plantar fasciitis. One patient out of 13 who had pain in his right foot revealed osteoarthritis of the talotibial and subtalar joints and os tibiale externum syndrome. Three patients out of 13 had bilateral foot pain. Of these, one patient suffered from os trigonum syndrome on the left side and from bilateral plantar fasciitis. The second patient with bilateral pain showed proximal intermetatarsal neoarticulations (between metatarsal bones III and IV) associated with increased fluoride uptake. The third patient revealed predominant pain in the right foot and showed right-sided osteoarthritis of the third metatarso-phalangeal joint and osteoarthritis of the first metatarsal sesamoid bone, as well as insertional tendinopathy of the anterior fibulotalar ligament and increased fluoride uptake in a degenerative lesion of the medial cuneiform on the left side (Table 1, Figs. 1, 2, 3 and 4) .
MRI findings
Of the 13 patients with changed therapeutic treatment, 11 had MR images available for retrospective analysis.
There were 15 findings from PET/CT to be compared with those from MRI. Unaware of the PET/CT results, the reviewer found that 6/15 (40%) of the findings from the PET/CT were prospectively visible in the MR images, 9/15 (60%) findings were new in the PET/CT images. After the reviewer was informed of the PET/CT findings, two of the nine (22%) new findings in the PET/CT images could, though less prominently, be retrospectively confirmed in the MR images. The other seven (78%) PET/CT findings could also not be confirmed retrospectively on MRI. One of these was rather discrete on PET/ CT ( Table 2) .
The nine new findings by PET/CT were (time between MRI and PET/CT in parentheses): an active os trigonum (6 months); an active sinus tarsi (8 days); an active nonunion after a distal tibial fracture (6 months); twice a plantar fasciitis (3 months, 22 days); subtalar osteoarthritis (2 days); an active os tibiale externum (2 days); an active neoarticulation between a third and forth metatarsal bone (3 months), and osteoarthritis of a third metatarsophalangeal joint (5 months). The active sinus tarsi and one active plantar fasciitis were retrospectively visible by MRI after the reviewer became aware of the findings. The six findings which were diagnosed by both modalities ('blind' evaluation) were as follows: an active calcaneal periostitis in PET/ CT medially to peroneal tendons, with concomitant tenosynovitis of the peroneal tendons on MRI (only visible after i.v. injection of contrast agent) (5 months); an active fragment of the left anterior calcaneal process (2 months); a calcaneo-navicular coalition (active on MRI, not active on PET/CT) (2 months); subtalar osteoarthritis, clearly active only on PET/CT (3 months); one osteoarthritis of the talotibial joint (2 days), and a osteoarthritis of a first metatarsal sesamoid bone (5 months).
Patient treatment
Prior to PET/CT in 6/13 patients, no specific therapy had been provided; in the other 7/13 patients infiltrations of different joints were performed. Therapeutic management changes induced by PET/CT in those 13 patients were as follows:
In four patients PET/CT found increased fluoride uptake in joints, and, subsequently, therapeutic infiltrations were performed in a more focused way or in a different location. Three patients without any special therapy prior to PET/CT received infiltrations afterwards. One patient who had received an infiltration prior to PET/CT was prescribed orthotics. One patient without specific therapy prior to PET-CT was treated with an infiltration on the right side in addition to insoles, due to the PET/CT findings. In three patients the PET/CT findings led to surgery: arthrodesis of the subtalar joint, and resection of a non-consolidated calcaneal fragment and of a calcaneo-navicular coalition. In one patient the PET/CT results prevented the foot surgeons from performing further foot-specific therapy and caused them to refer the patient to pain specialists (Table 1) .
Discussion
In our study fluoride PET/CT, using a specific foot protocol, had a substantial impact on therapeutic decision making by foot and ankle surgeons. PET/CT delivered important additional information compared to prior morphologic imaging by MRI and/or CT. Therapeutic management was changed in almost one-half of all patients in our study (46%).
Recently, Rüdisüli et al. published a study investigating SPECT/CT in 54 patients with foot pain as their main symptom. In their study 24 patients showed osteoarthritis, nine patients showed osteochondrosis dissecans and 18 patients revealed miscellaneous findings such as fractures, osteonecroses, a bone tumor, plantar fasciitis, talocalcanear coalitions, osteomyelitis and stress reactions. Three patients had completely normal findings. The therapeutic impact of SPECT/CT on patient treatment was not assessed [15] . With the worldwide shortage of molybdenum [17, 18] , the increasing availability of PET scanners and the superior image quality [2] of fluoride-PET imaging generates increasing interest.
The dedicated foot-fluoride PET/CT protocol is highly sensitive for the detection of metabolically active bone lesions, especially osteoarthritis. Combination with a thinslice CT scan provides precise anatomic location of lesions with increased bone turnover and can be used, for instance, to guide therapeutic local infiltrations.
In the majority of our patients PET/CT led to therapeutic joint infiltrations with anesthetics and corticosteroids (in eight patients) but also to surgery (in three patients) and the prescription of insoles/orthotics (in two patients). It could be hypothesized that patients with fluoride-active joints in the foot would respond better to local therapeutic injections than those with inactive joints, as has been shown in facet joint osteoarthritis with conventional bone scanning [19] . Our study has several limitations. First, the time interval between PET/CT and MRI as standard of reference showed a wide range in this patient population (i.e., from 2 days to 6 months in those patients whose therapeutic management had been changed, Table 2 ). Our study would have been more rigorous if the MRI had been performed closer in time to the PET/CT and with a standardized imaging protocol. Six findings could be seen both on PET/CT and MRI ('blinded' evaluation). In one case no active lesion at all was seen on PET/CT, although morphologic information was confirmed (patient no. 7)
Interestingly, one finding on PET/CT of possible periostitis corresponded to a soft-tissue finding on MRI after i.v. injection of contrast agent (tenosynovitis of peroneal tendons, patient no. 5) as an indirect sign of concomitant increased bone activity.
The results of this study suggest the complementary usefulness of PET/CT and MRI for patients with unclear foot pain.
Second, this study evaluated impact on management rather than outcome-an accepted approach in fluoro-2-deoxy-Dglucose (FDG) PET/CT oncology literature, as outcome studies are more difficult to perform [20, 21] . Further studies have to confirm that [ Third, the study has a selection bias, because patients were only referred to PET/CT when imaging and/or clinical diagnosis had failed to lead to an obvious diagnosis.
However, it is a standard approach to use a new imaging technology first on patients for whom other imaging has failed to provide a conclusive diagnosis.
In our experience [ 18 F]fluoride PET/CT is a highly sensitive tool showing many lesions with different uptake intensities in both feet with and without concomitant morphological changes. Interpretation of these multiple uptakes might be difficult.
A thorough history and adequate clinical examination (i.e., pain location in particular, trauma, surgery) are of utmost importance to avoid misinterpretation of the imaging findings. Our study population included patients with and without a history of trauma and/or surgery. The number of patients was limited, and the results of this preliminary study should be confirmed in more and specifically selected patients.
The effective dose equivalent is 0.023 mSv/MBq for [ 18 F]fluoride [22] , which is a maximum effective dose equivalent to 6.97 mSv in this study. The wide range of injected activity from 97-303 MBq is explained by the fact that we realized with increasing use of fluoride in our institution that an administered activity of 100-150 MBq is quite adequate to provide diagnostic images. With this 'low dose' protocol, the radiation burden of fluoride PET-CT is comparable to that of conventional SPECT/CT. Another advantage is the short uptake time of approximately 30 min pared to those of SPECT and bone scanning, and the higher costs [3, 23] . The cost effectiveness of fluoride PET/CT imaging in the diagnosis of orthopedic diseases should be analyzed in further studies [23, 24] . 
